-
-
-
-
-
-
-
GRI Bio reports gene expression data from IPF trial shows tissue repair
-
-
-
-
-
-
-
GRI Bio closes $8 million public offering with warrants
-
-
-
-
-
-
-
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
-
-
-
-
-
-
-
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results
-
-
-
-
-
-
-
GRI Bio Announces Closing of $5.0 Million Public Offering
-
-
-
-
-
-
-
GRI Bio Participates in a Virtual Investor CEO Connect Segment
-
-
-
-
-
-
-
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
-
1,155,240 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

